
Press Release

Alkem reports 14% revenue growth in Q2FY27

Mumbai, November 12, 2026: Alkem Laboratories Ltd. today announced its standalone and consolidated financial results for the second quarter ended September 30, 2026. The Board of Directors took record of these results at its meeting held in Mumbai today.

Q2FY27 Key Financial Metrics



Commenting on the results, Mr. Sandeep Singh, MD of Alkem, said, *"Our Q2FY27 performance reflects continued momentum in the India business, supported by focused execution across our acute and chronic portfolios. The international business delivered steady progress despite continued pricing pressure in the US, with volume growth providing support. During the quarter, we also expanded our MedTech presence through the addition of Occlutech, while improving execution and operating performance at Enzene remains a key priority. We will continue to focus on strengthening our core business, improving productivity and deploying capital prudently to build sustainable growth across pharmaceuticals, biotech and MedTech."*

We are pleased to welcome Dr. Amrut Naik as our Chief Executive Officer and wish him success in his new role.

Q2 FY27 Key Financial Highlights

- Total Revenue from Operations was ₹45,520 million, with YoY growth of 13.8%.
  - India sales were ₹30,275 million, YoY growth of 9.5%.
  - International sales were ₹14,540 million, with YoY growth of 22.3%.
- Biotech sales were ₹704 million, with YoY degrowth of 35%
- MedTech sales were ₹1,331 million (including Occlutech), integrated Occlutech from Q2FY27 onwards.
- EBITDA at ₹10,252 million, resulted in an EBITDA margin of 22.5%, a growth of 11.3% YoY.
- R&D expenses for Q2 FY27 were ₹1,953 million, or 4.3% of total revenue from operations, vs. ₹1,302 million in Q2 FY26 at 3.3% of total revenue from operations.
- Profit before tax (before exceptional item) was ₹ 9,646 million, YoY growth of 7.7%.
- Net Profit (after Non-Controlling interest) was ₹6,753 million, YoY de-growth of 11.7%.
- Net Cash stood at INR 49,054 mn (as on 30 September 2026)

Q2FY27 Operational Highlights

Domestic Business Key Highlights

- The contribution of domestic sales to total sales was 68% vs. 70% in Q2 FY26.
- According to IQVIA (SSA) data, for Q2 FY27:

- The Company registered a growth of 13.8% YoY at par with Indian Pharmaceutical Market (IPM), growth of 13.8%.
- Acute segment reported growth of 12.1% at par with IPM growth of 12.3%.
- Chronic segment reported growth of 22.4% vs. IPM which grew by 16%, +640 bps outperformance.
- We have outperformed IPM in eight key focused therapies: VMN ~1.2x, Pain ~1.5x, Anti-Diabetic ~1.5x, Cardiac by 1.1x, Urology by 1.1x, Respiratory ~1.6x, Neuro/CNS by 1.1x and Derma ~1.6x.

International Business Key Highlights

- US sales were ₹7,830 million, YoY growth of 2.4%.
- US business sales contributed 17% to total sales in Q2 FY27 vs. 19% in Q2 FY26.
- Non-US sales were ₹6,710 million, YoY growth of 58%. Excluding Occlutech, Non-US sales grew 28.6% YoY.
- Non-US business sales contributed 15% to total sales in Q2 FY27 v.s. 11% in Q2 FY26.

Facility Regulatory Status

Facility	Capability	Inspection Date	Regulatory Status
Baddi (India)	Formulations	Mar-24	EIR Received in June 2024
Daman (India)	Formulations	Apr-26	Official Action Indicated (OAI) in Aug 2026. Response submitted, remediation in progress
Taloja R&D (India)	Bioequivalence Centre	May-26	EIR Received in June 2026
Ankleshwar (India)	API	Apr-23	EIR Received in July 2023
Mandva (India)	API	Oct-26	Successful inspection with zero observations
California (USA)	API	Sep-25	EIR Received in Oct 2025

About Alkem: Alkem Laboratories Ltd. is the sixth - largest pharmaceutical company in the Indian market, with a legacy spanning over 50+ years of providing high-quality medicines to patients. It holds a dominant position in the therapy areas of anti-infectives, gastrointestinal disorders, pain management, and supplements. It also has a growing portfolio of products in chronic therapies, including diabetes, neurology, dermatology, and urology. It has 20+ state-of-the-art manufacturing facilities and cutting-edge research and development (R&D) centres to develop and manufacture generic formulations, active pharmaceutical ingredients (APIs) and biosimilars. Apart from India, the company has a meaningful presence in the US, Latin America, Australia, Europe and several other Asian countries. "Inspiring Healthier Lives" is at the core of the organization's values and culture, reinforcing its steadfast commitment to improving global health. For more information, please visit www.alkemlabs.com and follow us on LinkedIn, Instagram, and Facebook.

Contact

Investors:
Smeett Jain
+91 91522 29327
smeett.jain@alkem.com

Media:
Richa K. Sinari
+91 98201 84988
alkemcorpcomm@alkem.com

ALKEM LABORATORIES LTD.
Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.
• Phone: +91-22-3982 9999 • Fax: 022-2495 2955
• Email: contact@alkem.com • Website: www.alkemlabs.com
• CIN: L00305MH1973PLC174201

Invite for Q2FY27 & H1FY27 Conference Call at 4.30 pm IST, November 12, 2026

Mumbai, November 04, 2026: Alkem Laboratories Ltd. (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) will hold a conference call for investors and analysts on Thursday, November 12, 2026, from 4:30 pm to 5:30 pm IST to discuss its Q2 and H1FY27 financial results. The call will follow the announcement of the Company's Q2 and H1FY27 financial results on Thursday, November 12, 2026.

Alkem Laboratories Ltd. will be represented on the call by:

Mr. Sandeep Singh – Managing Director
Dr. Amrut Naik – Chief Executive Officer
Mr. Dishant Hitesh Doshi – Deputy Chief Financial Officer

Motilal Oswal Securities Ltd. will host the call.

Details of the Conference call are as follows

Time	4:30 pm IST (GMT + 5:30) on Thursday, November 12, 2026.

Dial in Details

India	+91 22 6280 1149 / +91 22 7115 8050

International Toll-Free

USA	1 866 746 2133	**UK**	0 808 101 1573
Singapore	800 101 2045	**Hong Kong**	800 964 448

Express Join with Diamond Pass

https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=5192390&linkSecurityString=2e6b8253ae

You are requested to dial in 10 minutes ahead of the scheduled start time.

Smeett Jain / Richa K. Sinari
Investor Relations / Media Alkem Laboratories Ltd.
Mobile: +91 91522 29327 / 98201 84988
Tel.: +91 22 3982 9999 Ext: 9447
E-mail: smeett.jain@alkem.com
richa.sinari@alkem.com

Tushar Manudhane
Institutional Research Analyst - Healthcare Motilal Oswal Securities Ltd.
Tel.: +91 22 6129 1536 / +91 82911 38039
E-mail: Tushar.Manudhane@motilaloswal.com

ALKEM
Inspiring Healthier Lives

Alkem Laboratories Ltd.

Q2 FY27 Results Presentation

12th November 2026



Safe Harbor Statement

This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact, including, but not limited to, those that are identified by the use of words such as "anticipates", "believes", "estimates", "expects", "intends", "plans", "predicts", "projects" and similar expressions. Risks and uncertainties that could affect us include, without limitation:

- *General economic and business conditions in India and other key global markets in which we operate;*
- *The ability to successfully implement our strategy, our research and development efforts, growth & expansion plans and technological changes;*
- *Changes in the value of the Rupee and other currency changes;*
- *Changes in the Indian and international interest rates;*
- *Allocations of funds by the Governments in our key global markets;*
- *Changes in laws and regulations that apply to our customers, suppliers, and the pharmaceutical industry;*
- *Increasing competition in and the conditions of our customers, suppliers and the pharmaceutical industry; and*
- *Changes in political conditions in India and in our key global markets.*

Should one or more of such risks and uncertainties materialize, or should any underlying assumption prove incorrect, actual outcomes may vary materially from those indicated in the applicable forward-looking statements. Any forward-looking statement or information contained in this presentation speaks only as of the date of the statement. We are not required to update any such statement or information to either reflect events or circumstances that occur after the date the statement or information is made or to account for unanticipated events, unless it is required by Law.

ALKEM - Advancing Healthcare. Enriching Patient Lives.

Building healthcare solutions across pharmaceuticals, biosimilars and MedTech to improve access, enhance the treatment experience & deliver better patient outcomes

ALKEM
Inspiring Healthier Lives

Pharma

India	International Markets
• **#3** player in **Acute Therapy**[1] • **#1** player in **Anti-Infectives TA**[1] • **#2** player in **VMN**[1] & **#3** player in **Pain**[1] • Rising **chronic** share • Building **bigger brands**	• **US** - **170 ANDAs** approvals[2] ➢ Focus on **differentiated & complex products** • **Other Key markets**: **Australia, Chile, UK, Germany** ➢ **Portfolio expansion** across select global markets

Biotech (Enzene)

Biosimilars portfolio in India and Intl. Mkts.
Commercialized Products

Biologics CDMO
Manufacturing in Pune and New Jersey, US
US FDA and EMA GMP compliant plants
Mammalian & Microbial mfg.

MedTech

Focus areas: **Orthopaedics & Cardiology**

Occlutech platform for global expansion (acquisition completed Jul-26)

1. IQVIA SSA MAT Sept'26 / QTR Sept'26, 2. As of 30 September 2026 (approvals include 18 tentative approvals) 3. FY26 Sales USD to INR 88.46 (31st March 2026)

Q2FY27 Performance at Glance

Key Financial Highlights


45,520 mn Revenue
13.8% YoY

10,252 mn EBITDA | **22.5% Margin[1]**
11.3% YoY


6,753 mn PAT[2] | **14.8% Margin[1]**
11.7% YoY

Region & Business wise sales split %

Sales (In INR mn & %)[3]



Sales (In INR mn & %)



1. Margins are calculated basis Total Revenue From Operations
2. PAT is after adjusting for Non Controlling interest
3. Includes Biotech + MedTech Sales

Highlights of Q2FY27

- Revenue from operations grew **13.8% YoY**; gross margin[1] expanded **220 bps** YoY to **67.2%**.
- India business grew **9.5%**; as per IQVIA SSA, Alkem grew 13.8% at par with IPM growth of 13.8%
  - ➢ Branded business grew **12.1%**; trade generics grew mid single digit.
  - ➢ Outperformed IPM in **8 therapies**; acute flattish, chronic +640 bps.
- US sales grew **2.4%**; Non-US international sales grew **58%** YoY[3].
- EBITDA margin at **22.5%**, down 50 bps YoY on account of Enzene CDMO operating cost & Occlutech acquisition.
- Net profit declined **11.7%**[1] YoY, mainly due to a higher effective tax rate.
- Net cash: **₹ 49,054 mn** (as at 30-Sept-26).


Regulatory Updates

- **Daman (India)** formulations facility: received **OAI**; response submitted; remediation in progress
- Successful inspection by US FDA at **Mandva, API plant** with zero observations


3. Non-US markets excluding Occlutech sales, QoQ Growth – 14% & YoY Growth – 29%

Key Financial Metrics


Total Revenue from Operations[1] (INR mn)




EBITDA (INR mn) & EBITDA Margins[3] %



Reported PAT[2] (INR Mn)



Total R&D (INR mn) & %[3]





1. Total Revenue From Operations Includes Other Operating Income
2. PAT is after adjusting for Non Controlling interest
3. Margins are calculated on Total Revenue from Operations

Note: R&D means Research & Development expenditure

Domestic Business Performance – Focus on Outperforming Market

India[3] sales grew 9.5% YoY






Highlights for the quarter

- Domestic sales grew 9.5% YoY% to INR 30,275 mn from INR 27,660 mn during the same period last year
  - Branded business grew **12.1%**; trade generics grew mid single digit.
- Acute grew 12.1% at par with IPM[1] growth of 12.3%; chronic grew 22.4% vs. IPM 16.0% outperforming IPM by 1.4x
- According to IQVIA SSA[1] data, for Q2 FY27:
  - ➢ Company registered a growth of 13.8% YoY at par with IPM growth of 13.8%,
  - ➢ Grown faster than IPM in 8 of IPM's key therapies
- Leading player in Semaglutide (GLP-1) parenteral market by volume[1]


Strengthening Patient Access Through New Launches

- Launched 26 products in H1FY27
- Multiple launches across various therapy areas
- Total Sales Force ~ 14,500[2] (MR's)

Overall performance in line with IPM[1]



Outperformance in Most of the Key Therapies[1]



1. IQVIA SSA QTR SEP'26 | Total Sales Force represents India Formulations MR's
3. Includes Branded Rx+ Trade Gx + Biotech+ MedTech Sales

Strong momentum from our mega brands has been pivotal in building robust brand franchises and consistently scaling them over the years

#2 'PAN'

Biggest Brand family in the IPM

15 Brands

in the IPM Top 300 ranks

31 Brands

Among the Top 3 ranks in their CVM[1] (Brands > ₹250 Mn)

Building large brand families defines our identity…

Brand family	# MAT Sept'21	# MAT Sept'26
> INR 15 Bn	-	1
> INR 5 Bn	1	2
> INR 1.5 Bn	7	11
> INR 500 Mn	13	17

Brand family > ₹15 Bn

PAN

Brand family > ₹5 Bn

CLAVAM

Brand family > ₹1.5 Bn


XONE TAXIM-O Uprise-D3 Gemcal PIPZO SUMOL DAPANORM Swich TRAXOL CHERi TAXIM

Source: Market data as per IQVIA SSA MAT Sep'26; 1. CVM is Covered Market


US Business Performance

US Sales Performance[1]

Sales (In INR mn)




Q2 FY27 Sales Contribution




Q2 FY27 Gr.	QoQ	YoY
	5.3%	2.4%

Continued Investment to build US pipeline (30-Sept-26)

ANDA approvals by quarter



Cumulative filings & approvals



^ Includes 18 tentative approval

Note: Company has separately filed 2 NDAs and 1 BLA & has received 2 NDAs approvals

1. Includes Biotech & MedTech sales


Highlights for the Quarter

- Sales grew 2.4% YoY to INR 7,830 mn; growth was largely led by volume growth
- Mid teens price erosion due to additional competition in select products


International Markets (Non-US) Business Performance

Strengthening International Markets[1] through Occlutech

Sales (In INR mn)



Q2 FY27 Sales Contribution



	QoQ	YoY
Q2 FY27 Gr.	40%	58%
Excluding Occlutech Gr.	14%	29%

Highlights for the Quarter

- Non-US sales grew 58% YoY to INR 6,710 mn, contributing 15% of total sales (14% in Q2 FY26)
- Growth was driven by double-digit growth in LATAM markets

1. Includes Biotech & MedTech sales

Biotech and MedTech

Building new growth engines

~₹ 704 mn
Q2 FY27 **Biotech sales**, De-grew 35% YoY

#5th Indian Company with a mAB in **Europe**

~₹ 1,331 mn
Q2 FY27 **MedTech sales** including Occlutech

Foot Print Across

Key Highlights

MedTech

- Occlutech was integrated from Q2 FY27; Q2 FY27 sales include Occlutech's contribution

Biosimilars

- Commercialized products in India, Europe (Germany and Spain) & in Mexico
- Denosumab EMA Vial presentation approved
- Marketing authorization for Denosumab received in South Korea

Alkem MedTech — Innovative. Affordable. Accessible

Musculoskeletal | **Cardiovascular**

Infrastructure & Capabilities

3 State-of-the-Art Manufacturing Facilities
Across **India, Germany & Turkey**

Comprehensive Product Portfolio in Target segment
Knee, Hip & Structural Heart

Medical Device R&D Talent Pool
2 R&D facilities across **Germany & Turkey**

Strong Supplier Ecosystem
Integrated network of Supplier eco-system powering speed-to-market

Note: mAB - monoclonal antibody; EMA - European Medicines Agency

ENZENE Biosciences Ltd.

Established biosimilars development expertise, supported by capabilities in continuous bioprocess manufacturing

Focus Areas - Disease Indication

Mammalian and Microbial mfg. in Pune;
CDMO Plant in US

R&D Facility – clone development, upstream & downstream processing, analytical services

Q2 FY27 – P&L Highlights

Particulars	Q2'FY27	% of Revenue	Q2'FY26	% of Revenue	YoY Growth	Q1'FY27	% of Revenue	QoQ Growth
Total Revenue from Operations	**45,520**	**100.0%**	**40,010**	**100.0%**	**13.8%**	**37,402**	**100.0%**	**21.7%**
Gross Profit (ex-Other income)	**30,572**	**67.2%**	**26,000**	**65.0%**	**17.6%**	**25,389**	**67.9%**	**20.4%**
EBITDA	**10,252**	**22.5%**	**9,208**	**23.0%**	**11.3%**	**7,661**	**20.5%**	**33.8%**
PBT (before exceptional items)	**9,646**	**21.2%**	**8,958**	**22.4%**	**7.7%**	**7,720**	**20.6%**	**25.0%**
PAT[1]	**6,753**	**14.8%**	**7,651**	**19.1%**	**-11.7%**	**5,200**	**13.9%**	**29.9%**
EPS	**56**		**64**		**-11.7%**	**43**		**29.9%**

1. PAT is after adjusting for Non controlling interest


H1 FY27 – P&L Highlights

Particulars	H1'FY27	% of Revenue	H1'FY26	% of Revenue	YoY Growth
Total Revenue from Operations	**82,921**	**100.0%**	**73,721**	**100.0%**	**12.5%**
Gross Profit (ex-Other income)	**55,961**	**67.5%**	**47,999**	**65.1%**	**16.6%**
EBITDA	**17,912**	**21.6%**	**16,598**	**22.5%**	**7.9%**
PBT (before exceptional items)	**17,366**	**20.9%**	**16,539**	**22.4%**	**5.0%**
PAT[1]	**11,953**	**14.4%**	**14,293**	**19.4%**	**-16.4%**
EPS	**100**		**120**		**-16.4%**

1. PAT is after adjusting for Non controlling interest

Balanced Ownership Structure

Shareholding as of 30 September 2026 | % Equity Share capital



MARKET SNAPSHOT

NSE / BSE	ALKEM / 539523
Shares outstanding	~120 Mn
Market capitalisation	Rs 617.4 Bn
Free-float market cap	Rs 310.5 Bn

PHARMA

Share price: Rs 5,163.5 on NSE as of 30th September 2026

Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks

Non-Institution – Public, Other Bodies Corporates, Clearing Members, Non-Resident Indians, Hindu Undivided Family & Trusts

Alkem Laboratories at a Glance

FY26 India-led franchise combines market leadership, operating scale and healthy profitability

01 MARKET LEADERSHIP

Relative position across key India metrics

Prescriptions **#3**

Value in IPM **#6**

Top 3 presence

4/7

4 of 7 largest IPM therapies

Leading player

Trade Generics segment

Leadership anchored in prescriptions, therapies and trade generics

02 SCALE

India remains the core of the operating platform

67.8%

Domestic revenue

₹ 1,47,123 Mn

Total Revenue³

17 brand families

₹ 1,000 Mn+ each²

14,500+

Field force⁴

03 PROFITABILITY

Margin profile and returns

Gross Profit margin	65.4%
EBITDA margin	20.4%
PAT margin	15.6%
ROCE (Pre-Tax)	29.6%

Healthy margin profile complemented by strong pre-tax returns

1. SMSRC MAT Feb'26 | 2. IQVIA SSA MAT Mar'26 | 3. Includes Other Operating Income | 4. Excludes Line Managers as of 31 March 2026

Key Awards & Recognition

Recognition across corporate excellence, people, innovation, patient impact and brand leadership

- **Corporate Excellence:** Pharma Company of the Year at the Financial Express Pharma Awards 2026.
- **People & Culture:** #26 among India's 100 Best Companies to Work For 2026 and #1 pharmaceutical company on the list.
- **Leadership:** Madhurima Singh recognised among Business Today's Most Powerful Women in Business for the second consecutive year.
- **Patient Safety:** Excellence in Anti-Counterfeiting Innovation at both Financial Express and BW Businessworld Pharma Awards 2026.
- **Biologics:** Most Promising Biologics Drug Pipeline at the Asia-Pacific Biopharma Excellence Awards 2026.
- **Digital Health:** AI in Patient Management at the DigipharmaX Awards 2025.
- **Data & Analytics:** Digital Excellence in Data Analytics at the DigipharmaX Awards 2025.
- **CSR:** CSR Programme of the Year at the Financial Express Pharma Awards 2026 for the Bihar cancer-care initiative.
- **Rural Healthcare:** Excellence in Rural Health Initiative at the BW Businessworld Pharma Awards 2026 for Anaemia Mukti Abhiyaan.
- **Community Impact:** FICCI CSR Award 2023–24 for health, drinking water, sanitation and hygiene.
- **Diabetes Awareness:** Asia Book of Records recognition for 29,704 diabetes screenings conducted in one month.
- **AMR Awareness:** Asia Book of Records recognition for a nationwide initiative promoting responsible antibiotic use.
- **Brand Leadership:** PAN ranked the No. 1 prescribed brand in the Indian pharmaceutical market for July–October 2025.
- **Marketing Innovation:** PAN and PAN-D recognised at ICMA 2025 and Brand Manthan 2025 for impactful brand communication.

Note: AMR: Antimicrobial Resistance.

THANK YOU

For any queries, contact:
Smeett Jain
Mobile: +91 91522 29327
E-mail: smeett.jain@alkem.com

Stay updated on

Disclaimer: This is a confidential email from Alkem Laboratories Limited. The contents of this email and any attachments are solely intended for the addressee(s) and in all likelihood contain information that is legally privileged. If you are not the intended recipient of this email, you are on notice of its status and we request you to kindly advise us by return email immediately. Please also simultaneously disregard the contents herein, delete this email from your computer and server and also destroy any physical copies, if created. You are hereby notified that any use, any form of reproduction, dissemination, copying, disclosure, modification, distribution and/or publication of this e-mail, its contents or its attachment/s other than by its intended recipient/s is strictly prohibited and may be construed unlawful. Alkem Laboratories Limited does not accept any liability for the views expressed in this email or for the consequences of any viruses that may be transmitted with this email. The content of this email is subject to copyright and no part hereof may be reproduced, adapted or transmitted without the written consent of Alkem Laboratories Limited.

Conserve to Preserve. Think before you Print.